Literature DB >> 21117945

Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use.

Thomas V Johnson1, Preeya K Gupta, Daljit K Vudathala, Ian A Blair, Angelo P Tanna.   

Abstract

PURPOSE: To determine the stability of bimatoprost, latanoprost, and travoprost under conditions of simulated daily use and varying degrees of thermal stress.
METHODS: Commercially available bimatoprost, latanoprost, and travoprost were obtained in their original bottles as distributed by the manufacturers. Bottles were stored in calibrated, nonhumidified, light-free incubators maintained at 27°C, 37°C, or 50°C for 3, 9, 15, or 30 days. Capped bottles were inverted and left uncapped for 1  min daily to simulate patient use; no drops were expelled. Bimatoprost concentration was analyzed using liquid chromatography with ultraviolet detection at 210  nm. Latanoprost and travoprost concentrations were analyzed by liquid chromatography/tandem mass spectrometry (MS/MS) using selected reaction monitoring.
RESULTS: Off-the-shelf control bottles of bimatoprost contained 102% of the labeled concentration. In all combinations of stress temperature and duration, mean bimatoprost concentration ranged from 100% to 116% of the labeled concentration with no measurable degradation. Off-the-shelf control bottles of latanoprost contained 115% of the labeled concentration. Mean latanoprost concentration ranged from 97% to 120% of the labeled concentration. Latanoprost was stable at 27°C. When stressed at 37°C or 50°C, latanoprost degraded at a rate of 0.15 or 0.29  μg/mL/day, respectively. Off-the-shelf control bottles of travoprost contained 120% of the labeled concentration. Mean travoprost concentration ranged from 83% to 142% of the labeled concentration. Travoprost was stable at 27°C and 37°C, although concentration measurements at 37°C exhibited high variability. When stressed at 50°C, travoprost degraded at a rate of 0.46  μg/mL/day.
CONCLUSIONS: Higher than expected concentrations for stressed drug samples are likely a result of evaporation. Under the conditions of thermal stress tested in this study, bimatoprost remained stable for all conditions tested. Latanoprost degradation was measurable only in samples stressed at 37°C and 50°C, whereas travoprost degradation was statistically significant only in samples stressed at 50°C.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21117945      PMCID: PMC3038126          DOI: 10.1089/jop.2010.0115

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  33 in total

1.  The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators.

Authors: 
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

Review 2.  Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.

Authors:  Stefan Holmstrom; Patricia Buchholz; John Walt; Jannie Wickstrøm; Mark Aagren
Journal:  Curr Med Res Opin       Date:  2005-11       Impact factor: 2.580

Review 3.  Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials.

Authors:  Philip C Maier; Jens Funk; Guido Schwarzer; Gerd Antes; Yngve T Falck-Ytter
Journal:  BMJ       Date:  2005-07-01

4.  Effects of travoprost 0.004% ophthalmic solution, six weeks after its laminated packaging had been removed, in primary open-angle glaucoma: a randomized, controlled, investigator-blinded study.

Authors:  Ricardo Reis; Lucia Cristina dos Santos; Marcos P Vila; Leopoldo Magacho
Journal:  Clin Ther       Date:  2004-12       Impact factor: 3.393

5.  Concentration of latanoprost ophthalmic solution after 4 to 6 weeks' use in an eye clinic setting.

Authors:  Rohit Varma; Jonathan Winarko; Tien Kiat-Winarko; Benjamin Winarko
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-01       Impact factor: 4.799

6.  Global data on visual impairment in the year 2002.

Authors:  Serge Resnikoff; Donatella Pascolini; Daniel Etya'ale; Ivo Kocur; Ramachandra Pararajasegaram; Gopal P Pokharel; Silvio P Mariotti
Journal:  Bull World Health Organ       Date:  2004-12-14       Impact factor: 9.408

7.  Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.

Authors:  Carol B Toris; Guilin Zhan; Shan Fan; Jaime E Dickerson; Theresa A Landry; Michael V W Bergamini; Carl B Camras
Journal:  J Glaucoma       Date:  2007-03       Impact factor: 2.503

8.  Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.

Authors:  K Sheng Lim; Cherie B Nau; Megan M O'Byrne; David O Hodge; Carol B Toris; Jay W McLaren; Douglas H Johnson
Journal:  Ophthalmology       Date:  2008-05       Impact factor: 12.079

9.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

10.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

View more
  5 in total

1.  [Original preparations versus generics--latanoprost: how similar is different?].

Authors:  M A Leitritz; H-P Lipp; B Voykov; F Ziemssen
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

2.  In vivo performance of a drug-eluting contact lens to treat glaucoma for a month.

Authors:  Joseph B Ciolino; Cristina F Stefanescu; Amy E Ross; Borja Salvador-Culla; Priscila Cortez; Eden M Ford; Kate A Wymbs; Sarah L Sprague; Daniel R Mascoop; Shireen S Rudina; Sunia A Trauger; Fabiano Cade; Daniel S Kohane
Journal:  Biomaterials       Date:  2013-10-04       Impact factor: 12.479

Review 3.  Evaluation of Physical Properties of Generic and Branded Travoprost Formulations.

Authors:  Meenakshi Wadhwani; Sanjay K Mishra; Dewang Angmo; Thirumurthy Velpandian; Ramanjit Sihota; Ankita Kotnala; Shibal Bhartiya; Tanuj Dada
Journal:  J Curr Glaucoma Pract       Date:  2016-08-05

Review 4.  Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution.

Authors:  Daniel Lee; Anand V Mantravadi; Jonathan S Myers
Journal:  Clin Ophthalmol       Date:  2017-07-10

5.  Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations.

Authors:  Dewang Angmo; Meenakshi Wadhwani; Thirumurthy Velpandian; Ankita Kotnal; Ramanjit Sihota; Tanuj Dada
Journal:  Int Ophthalmol       Date:  2016-06-22       Impact factor: 2.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.